86 hasil
Menampilkan 1–20 · 0,21 detik · RSS
Melanoma Management
Scopus
ISSN 2045-0893 · Taylor & Francis Group · 86 artikel di indeks
-
Artikel Jurnal
Insurance, race, and socioeconomic disparities in systemic therapy receipt for melanoma in the United States: a systematic review
Background Although evidence suggests disparities in melanoma treatment, no comprehensive summary exists on whether insurance type, race/ethnicity, or socioeconomic status consistently influence systemic therapy receipt. Understanding these associations may inform strategies to reduce…
-
Artikel Jurnal
A bibliometric analysis of sentinel lymph node biopsy in melanoma of the top 90 cited publications
Background This bibliometric analysis aims to describe research trends and assess the methodological quality of the highest-impact SLNB research in melanoma.Methods We identified the 90 most cited publications on SLNB in melanoma using Web of Science, covering all available journal years (from 2005…
-
Artikel Jurnal
Beliefs and attitudes toward skin biopsy as a diagnostic tool: a cross-sectional survey among US patients
Aims Skin biopsy remains the diagnostic gold standard for assessing melanocytic lesions, yet its use is influenced by provider experience and scope of practice. This study evaluated patient attitudes toward biopsy, barriers such as discomfort and needle phobia, and interest in noninvasive…
-
Artikel Jurnal
Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes
Cutaneous melanoma is a highly aggressive skin cancer with rising incidence, driven by risk factors such as ultraviolet exposure, genetic predisposition, and immunosuppression. While surgical excision remains the primary treatment, interest in chemoprevention strategies is growing. Numerous natural…
-
Artikel Jurnal
Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients
Background Adjuvant immunotherapy and targeted therapy are now the standard of care for patients with resected stage IIIA–IV melanoma. However, little is known regarding its efficacy in real-world patients who were not represented in these landmark trials.Methods This retrospective study included…
-
Artikel Jurnal
Primary dermal melanoma: a rare subtype of cutaneous melanoma
Primary dermal melanoma (PDM) is a rare subtype of cutaneous melanoma, with involvement of the dermis/subcutaneous tissue or both, but no involvement of the epidermis. PDM could not be distinguished histologically from metastasis of primary cutaneous melanoma. PDM has a longer life expectancy…
-
Artikel Jurnal
Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series
Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown efficacy in treating cancers with homologous recombination deficiency (HRD), including subsets of melanoma. However, the potential synergy between PARPi and standard melanoma therapies remains understudied. Here, we report two cases of…
-
Artikel Jurnal
Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS)
Aim The collaborative ocular melanoma study (COMS) reported similar survival between plaque brachytherapy (a type of interventional radiotherapy) and enucleation for medium-sized choroidal melanomas. We aimed to quantify the mortality differences required to achieve statistical significance and…
-
Artikel Jurnal
Screening and novel diagnostic technologies for melanoma: an update
Melanoma incidence has increased over recent decades, yet mortality has been relatively stable. This pattern has raised concern that many newly diagnosed melanomas, particularly melanoma in situ, may reflect overdiagnosis rather than a true increase in disease burden. Screening can detect melanoma…
-
Artikel Jurnal
Bridging gaps throughout a patient’s journey with melanoma: a systematic review
Background Melanoma is one of the most fatal skin cancers, with rising incidence and mortality worldwide. From diagnosis to treatment, patient experiences often involve anxiety, symptom burden, and limited access to information which profoundly impacts health outcomes.Objective This systematic…
-
Artikel Jurnal
Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project
The management of advanced, unresectable, or metastatic BRAFV600-mutated melanoma is complex, particularly regarding therapy sequencing with targeted therapies (TT) and immune checkpoint inhibitors (ICI). The REMINISCENCE project aimed to enhance individualized therapy approaches by analyzing case…
-
Artikel Jurnal
Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials
Background Vemurafenib (Zelboraf®, Roche), approved by the FDA in 2011 for unresectable and metastatic melanoma and Erdheim-Chester Disease, has been explored in trials for other BRAF-mutated cancers. Despite 12 years of clinical use, the risk-benefit profile for off-label indications remain…
-
Artikel Jurnal
Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients
Background Advances in cancer therapy have improved patient outcomes, but cardiotoxicity remains a significant risk. In melanoma patients treated with BRAF and MEK inhibitors, monitoring left ventricular ejection fraction (LVEF) during treatment is recommended to detect cardiac dysfunction. Despite…
-
Artikel Jurnal
Patient preferences for stages II–IV melanoma treatments in the UK: results from a cross-sectional study
Aim To understand patient preferences for treatment attributes in adjuvant and metastatic melanoma in the UK.Materials and Methods Patients with stages II–IV melanoma completed an online survey from November 2022 to February 2023 comprising two discrete choice experiments (DCE) exploring efficacy…
-
Artikel Jurnal
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial
Metastatic uveal melanoma (UM) patients often initially present with limited symptoms despite a poor prognosis, complicating communication with patients and caregivers. Early Together (NCT04728113) is a randomized Phase III trial that integrates early palliative care through systematic joint visits…
-
Artikel Jurnal
BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy
Aims In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.Patients and Methods We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing…
-
Artikel Jurnal
A rare and challenging case of amelanotic subungual melanoma from Syria
Subungual melanoma accounts for 1.9% of cutaneous melanomas. Amelanotic cases, comprising 15–25%, poses a significant diagnostic challenge because it can be misdiagnosed as other traumatic, inflammatory, or neoplastic conditions. This often leads to delayed diagnosis and subsequently, a poor…
-
Artikel Jurnal
Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up
Aim: This study determined the characteristics of patients with early-stage melanoma (IA-IIA) who later had stage IV recurrence.Patients & methods: We retrospectively examined 880 melanoma patients and identified those who progressed to stage IV disease from an initial early-stage (n = 50).Results…
-
Artikel Jurnal
Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review
Aim: This study summarized the existing evidence on the outcomes and safety of anti-PD-1s, anti-PD-L1s and anti-CTLA-4s in pediatric patients with melanoma.Materials & methods: MEDLINE® and Embase were searched from database inception to 01-12-2023.Results: Of 1537 records identified, 27 studies…
-
Artikel Jurnal
Disulfidptosis-related classification patterns and tumor microenvironment characterization in skin cutaneous melanoma
Aim: To identify distinct disulfidptosis-molecular subtypes and develop a novel prognostic signature. Methods/materials: We integrated into this study multiple SKCM transcriptomic datasets from the Cancer Genome Atlas database and Gene Expression Omnibus dataset. The consensus clustering algorithm…